315 related articles for article (PubMed ID: 17952838)
21. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance.
Wang ZQ; Cefalu WT
Curr Diab Rep; 2010 Apr; 10(2):145-51. PubMed ID: 20425574
[TBL] [Abstract][Full Text] [Related]
22. The metabolic syndrome: mechanisms, epidemiology, and clinical implications.
Postgrad Med; 2003 Dec; 114(6 Suppl Managing Metabolic):17-27. PubMed ID: 19667650
[TBL] [Abstract][Full Text] [Related]
23. Smoking-induced metabolic disorders: a review.
Berlin I
Diabetes Metab; 2008 Sep; 34(4 Pt 1):307-14. PubMed ID: 18468932
[TBL] [Abstract][Full Text] [Related]
24. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
Cannon CP
Am J Cardiol; 2008 Dec; 102(12A):5L-9L. PubMed ID: 19084083
[TBL] [Abstract][Full Text] [Related]
25. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
Nathanson D; Nyström T
Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus.
Hayden MR; Sowers JR
J Cardiometab Syndr; 2008; 3(3):129-31. PubMed ID: 18983326
[No Abstract] [Full Text] [Related]
27. Angiotensin II, corticosteroids, type II diabetes and the metabolic syndrome.
Vinson GP
Med Hypotheses; 2007; 68(6):1200-7. PubMed ID: 17134848
[TBL] [Abstract][Full Text] [Related]
28. [Effect of food diet supplements with chromium on the clinical and metabolic parameters in type 2 diabetic patients].
Sharafetdinov KhKh; Meshcheriakova VA; Plotnikova OA; Mazo VK; Gmoshinskiĭ IV; Nechaeva SV
Vopr Pitan; 2004; 73(5):17-20. PubMed ID: 15754482
[TBL] [Abstract][Full Text] [Related]
29. Improvement of blood glucose control and insulin sensitivity during a long-term (60 weeks) randomized study with amino acid dietary supplements in elderly subjects with type 2 diabetes mellitus.
Solerte SB; Fioravanti M; Locatelli E; Bonacasa R; Zamboni M; Basso C; Mazzoleni A; Mansi V; Geroutis N; Gazzaruso C
Am J Cardiol; 2008 Jun; 101(11A):82E-88E. PubMed ID: 18514633
[TBL] [Abstract][Full Text] [Related]
30. Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers.
Toh SA; Rader DJ
Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):1007-22. PubMed ID: 18666851
[TBL] [Abstract][Full Text] [Related]
31. Obesity and the metabolic syndrome in the elderly--a mini-review.
Lechleitner M
Gerontology; 2008; 54(5):253-9. PubMed ID: 18841025
[TBL] [Abstract][Full Text] [Related]
32. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Steiner G
Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
[TBL] [Abstract][Full Text] [Related]
33. [Metabolic syndrome as a precursor of diabetes mellitus type 2 and cardiovascular diseases].
Shestakova MV; Butrova SA; Sukhareva OIu
Ter Arkh; 2007; 79(10):5-8. PubMed ID: 18154136
[No Abstract] [Full Text] [Related]
34. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
Chapman MJ; Sposito AC
Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
[TBL] [Abstract][Full Text] [Related]
35. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
36. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes.
González S; Jayagopal V; Kilpatrick ES; Chapman T; Atkin SL
Diabetes Care; 2007 Jul; 30(7):1871-3. PubMed ID: 17468359
[No Abstract] [Full Text] [Related]
37. Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients.
Yun JE; Sull JW; Lee HY; Park E; Kim S; Jo J; Lee SJ; Kim SY; Choi YJ; Jee SH; Huh KB
Diabetes Metab Res Rev; 2009 Mar; 25(3):259-65. PubMed ID: 19214966
[TBL] [Abstract][Full Text] [Related]
38. Chromium as an essential nutrient for humans.
Anderson RA
Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 2):S35-41. PubMed ID: 9380836
[TBL] [Abstract][Full Text] [Related]
39. Comparing metabolic effects of six different commercial trivalent chromium compounds.
Preuss HG; Echard B; Perricone NV; Bagchi D; Yasmin T; Stohs SJ
J Inorg Biochem; 2008 Nov; 102(11):1986-90. PubMed ID: 18774175
[TBL] [Abstract][Full Text] [Related]
40. Metabolic syndrome and the menopause.
Kaaja RJ
Menopause Int; 2008 Mar; 14(1):21-5. PubMed ID: 18380957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
